A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Public ClinicalTrials.gov record NCT00855218. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT00855218
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 307 participants
Conditions and interventions
Conditions
Interventions
- Sorafenib (Nexavar, BAY43-9006) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- Jun 30, 2011
- Completion
- Jan 31, 2013
- Last update posted
- Aug 17, 2017
2009 – 2013
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | La Jolla | California | 92037 | — |
| Not listed | Los Angeles | California | 90095-7077 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Gainesville | Florida | 32610-0316 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Orlando | Florida | 32804 | — |
| Not listed | Atlanta | Georgia | 30309-1231 | — |
| Not listed | Ann Arbor | Michigan | 48109-0330 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Abbott Northwestern Hospital | Minneapolis | Minnesota | 55407 | — |
| Not listed | St Louis | Missouri | 63104 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Columbus | Ohio | 43210-1240 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Richmond | Virginia | 23249 | — |
| Not listed | Seattle | Washington | 98101 | — |
| Not listed | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00855218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00855218 live on ClinicalTrials.gov.